SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (date of earliest event reported): November 6,
2007.
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
6121
Hollis Street
Emeryville,
California 94608
(Address
of principal executive offices)
(510)
350-2940
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Statements
made in this Report that are not historical facts may constitute forward-looking
statements that are subject to risks and uncertainties that could cause actual
results to differ materially from those discussed. Such risks and
uncertainties include but are not limited to those discussed in this report
and
in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange
Commission. Words such as “expects,” “may,” “will,” “anticipates,” “intends,”
“plans,” “believes,” “seeks,” “estimates,” and similar expressions identify
forward-looking statements.
Section
7 - Regulation FD
Section
7.01 - Regulation FD Disclosure
The
press
release filed as Exhibit 99.1 is incorporated by reference.
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
release dated November 6, 2007
|
Section
9-Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
release dated November 6, 2007
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
BIOTIME,
INC.
|
|||
|
Date: November
6, 2007
|
By
|
/s/
Judith Segall
|
|
|
Vice
President & Secretary
Member,
Office of the President
|
|||
2
|
Exhibit
Number
|
Description
|
|
|
Press
release dated November 6, 2007
|
3
Exhibit
99.1
|
BIOTIME,
INC.
``````````````````````````````````````````````````` |
6121
Hollis Street
Emeryville,
CA 94608
Tel:
510-350-2940
Fax:
510-350-2948
www.biotimeinc.com
|
For
Further Information:
Judith
Segall (510) 350-2940
BIOTIME,
INC. TO PRESENT PLANS FOR REGENERATIVE MEDICINE AT
ACUMEN
BIOFIN RODMAN & RENSHAW 9TH ANNUAL HEALTHCARE
CONFERENCE
EMERYVILLE,
CA, November 6, 2007 – BioTime, Inc.
(OTCBB: BTIM) today announced that Michael D. West, Ph.D., Chief Executive
Officer, will present an update of the Company's product development programs
at
10:35 a.m. EDT on Tuesday, November 6, 2007, at the Acumen BioFin Rodman &
Renshaw 9th
Annual Healthcare Conference, which is being held November 5-7, 2007 at the
New
York Palace Hotel in New York.
The
update will include information about BioTime's new initiative in regenerative
medicine. Regenerative medicine is the new field of biotechnology
based on the isolation of human embryonic stem (hES) cells. These cells are
totipotent, meaning that they have the potential to become all of the cell
types
in the human body. These new technologies may be a source of
therapies for many degenerative diseases, such as those of aging, that currently
have enormous unmet needs. Researchers will have to develop means of
manufacturing purified populations of the many hundreds of cell types in the
human body in order to test the efficacy of transplanting these cells in
patients to replace their damaged or diseased tissues or organs.
Dr.
West
will discuss BioTime’s plans to focus on near-term commercialization
opportunities presented by these research programs. BioTime believes that the
development of products for use in stem cell research provides an opportunity
to
commercialize products more quickly, using less capital, than developing
therapeutic products. BioTime’s plan is to market to companies and
academic researchers in this growing industry some of the tools they need to
attain their goals.
BioTime
plans to launch three kinds of research products in the next two
years. The first product is a commercial embryome database that will
provide a map that researchers may use to navigate the complexities of human
development and to identify the many hundreds of cell types coming from hES
cells. Like the field of “genomics,” where companies mapped the human
DNA, BioTime believes that there is an important need for a map or the human
“embryome” in stem cell research. This map would take the form of a
relational data base that would permit researchers to chart the cell lineages
of
human development, the genes expressed in those cell types, and antigens present
on the cell surface of those cells that can be used in
purification. The Company plans to launch this web-based database in
late 2007 or the early part of 2008.
Second,
in order to manufacture specific cell types from hES cells, researchers need
to
use factors that signal to hES cells to become a desired cell
type. BioTime plans to develop growth and differentiation factors,
and hopes to launch the first of these products beginning in
2008. BioTime may market these reagents from a new BioTime
website.
Lastly,
the Company will discuss its third category of near-term products to be launched
beginning in 2009. These new products are purification ligands useful
to researchers in purification and quality control analysis of products in
regenerative medicine.
Dr.
West
will also discuss BioTime’s physiologically balanced blood plasma volume
replacement products, Hextend®, PentaLyte®,
and HetaCool®. BioTime
and Argonne National Laboratory recently announced plans to engage in a joint
research program in hypothermic medicine using Hextend and HetaCool in
conjunction with Argonne’s ice slurry technology.
The
live
audio webcast will be available at http://www.wsw.com/webcast/rrshq12/btim.ob
or
via BioTime's Investor Relations at www.biotimeinc.com. An archive of the
presentation will be available for 90 days.
About
BioTime, Inc.
BioTime,
headquartered in Emeryville, California, develops blood plasma volume expanders,
blood replacement solutions for hypothermic (low temperature) surgery, organ
preservation solutions, and technology for use in surgery, emergency trauma
treatment and other applications. BioTime’s lead product Hextend is manufactured
and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp.
under exclusive licensing agreements. BioTime has recently entered
the field of regenerative medicine where it plans to develop new medical and
research products using embryonic stem cell technology. Information
about BioTime can be found on the web at www.biotimeinc.com. Hextend®,
PentaLyte®, and HetaCool® are
registered
trademarks of BioTime, Inc.
Forward
Looking Statements
The
matters discussed in this press release include forward-looking statements
which
are subject to various risks, uncertainties, and other factors that could cause
actual results to differ materially from the results anticipated. Such risks
and
uncertainties include but are not limited to the success of BioTime in
developing new stem cell products and technologies; results of clinical trials
of BioTime products; the ability of BioTime and its licensees to obtain
additional FDA and foreign regulatory approval to market BioTime products;
competition from products manufactured and sold or being developed by other
companies; the price of and demand for BioTime products, and the
ability of BioTime to raise the capital needed to finance its current and
planned operations. Other factors that could affect BioTime’s
operations and financial condition are discussed in BioTime’s Annual Report on
Form 10-KSB filed with the Securities and Exchange Commission.
Click
here to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0